PPBTPURPLE BIOTECH LTD.

Nasdaq purple-biotech.com


$ 0.52 $ 0.01 (1.96 %)    

Wednesday, 15-May-2024 15:50:10 EDT
QQQ $ 452.83 $ 3.91 (0.87 %)
DIA $ 399.31 $ 3.73 (0.94 %)
SPY $ 529.09 $ 3.17 (0.6 %)
TLT $ 92.14 $ 1.28 (1.41 %)
GLD $ 220.89 $ 2.79 (1.28 %)
$ 0.5
$ 0.51
$ 0.50 x 100
$ 0.00 x 0
$ 0.51 - $ 0.52
$ 0.30 - $ 1.99
76,145
na
12.87M
$ 1.11
$ 1.19
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-purple-biotech-maintains-10-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Purple Biotech (NASDAQ:PPBT) with a Buy and maintains $10 price target.

 chardan-capital-maintains-buy-on-purple-biotech-maintains-11-price-target

Chardan Capital analyst Daniil Gataulin maintains Purple Biotech (NASDAQ:PPBT) with a Buy and maintains $11 price target.

 hc-wainwright--co-reiterates-buy-on-purple-biotech-maintains-10-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Purple Biotech (NASDAQ:PPBT) with a Buy and maintains $10 price target.

 purple-biotech-q4-eps-019-inline

Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.19) per share which met the analyst consensus estimate. This is a...

 hc-wainwright--co-reiterates-buy-on-purple-biotech-maintains-10-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Purple Biotech (NASDAQ:PPBT) with a Buy and maintains $10 price target.

 purple-biotech-says-determined-100mgkg-is-the-recommended-phase-2-dose-for-nt219-in-combination-with-cetuximab-in-the-treatment-of-head-and-neck-cancer-based-on-its-phase-12-dose-escalation-study

NT219 is a first-in-class small molecule dual inhibitor of IRS1/2 and STAT3. The Phase 1 dose escalation study is being conclud...

 why-green-giant-shares-are-trading-lower-by-around-37-here-are-20-stocks-moving-premarket

Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Gre...

 hc-wainwright--co-maintains-buy-on-purple-biotech-raises-price-target-to-10

HC Wainwright & Co. analyst Emily Bodnar maintains Purple Biotech (NASDAQ:PPBT) with a Buy and raises the price target f...

 purple-biotech-q3-eps-023-inline-159m-in-cash-cash-equivalents-and-short-term-deposits-in-october-2023-the-company-raised-an-additional-gross-amount-of-5m-extended-the-cash-runway-to-the-second-half-of-2025

Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.23) per share which met the analyst consensus estimate. This is a...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION